{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q9BQ51",
      "entity_text" : "PD-L2",
      "entity_type" : "protein"
    },
    "participant_a" : [ {
      "in_model" : true,
      "identifier" : "uaz:UAZ00306",
      "entity_text" : "Nivolumab",
      "entity_type" : "protein"
    }, {
      "in_model" : true,
      "identifier" : "uniprot:P18621",
      "entity_text" : "PD-1",
      "entity_type" : "protein"
    } ],
    "hypothesis_information" : false
  },
  "verbose_text" : "Nivolumab binds to PD-1 on the surface of T cells, and blocks the interaction between PD-1 and its ligands, PD-L1, and PD-L2.",
  "reading_complete" : "2020-08-03T14:29:23Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T14:28:31Z",
  "trigger" : "blocks",
  "evidence" : [ "Nivolumab binds to PD-1 on the surface of T cells, and blocks the interaction between PD-1 and its ligands, PD-L1, and PD-L2" ],
  "pmc_id" : "5412830",
  "score" : 0
}